When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Research news of note last week included US biotech Crinetics Pharmaceuticals releasing new Phase III data on its acromegaly drug candidate Palsonify (paltusotine). AstraZeneca announced positive ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

In a major contribution to identifying rare diseases, Iliyas Rashid and his team at the Tata Institute for Genetics and ...

Drugmaker Sarepta Therapeutics says it won't comply with a request from U.S. regulators to halt all shipments of its gene ...

Sarepta Therapeutics announced late Friday evening that it will not comply with the Food and Drug Administration's ...